Socioeconomic Assessment and Impact of Social Security on Outcome in Patients Admitted with Suspected Coronary Chest Pain in the City of Salta, Argentina

Table 4

(a) Mortality adjusted for gender and age at 5-year follow-up in four groups: low, middle, and high socioeconomic groups, respectively, and patients without social security. (b) Mortality adjusted for several variables at 5-year follow-up in four groups: low, middle and high socioeconomic groups, respectively, and patients without social security.

(a)  

Mode of death at 5 y FU		Low	Middle	High	HR (95% CI)	𝑃 value
All patients
AC mortality, 𝑛 (%)		102 (22.8)	57 (15.0)	14 (9.0)	0.46 (0.26–0.83)	0.009
C mortality, 𝑛 (%)		55 (12.3)	29 (7.7)	8 (5.2)	0.42 (0.19–0.94)	0.035
SCD, 𝑛 (%)		36 (8.0)	18 (4.7)	5 (3.2)	0.47 (0.18–1.23)	0.123
	Without social security				*HR (95% CI)
All patients
AC. mortality, 𝑛 (%)	38 (24.5)	64 (21.3)	57 (15.4)	14 (9.0)	0.46 (0.25–0.88)	0.018
C. mortality, 𝑛 (%)	24 (15.5)	31 (10.3)	29 (7.8)	8 (5.2)	0.38 (0.16–0.89)	0.027
SCD, 𝑛 (%)	15 (9.7)	21 (7.0)	18 (4.9)	5 (3.2)	0.46 (0.16–1.26)	0.132
TnT positive patients
AC. mortality, 𝑛 (%)	24 (35.8)	36 (35.0)	42 (27.1)	10 (15.9)	0.49 (0.23–1.06)	0.069
C. mortality, 𝑛 (%)	15 (22.4)	16 (15.5)	22 (14.2)	6 (9.5)	0.45 (0.16–1.25)	0.126
SCD, 𝑛 (%)	8 (11.9)	13 (12.6)	13 (8.4)	4 (6.3)	0.73 (0.22–2.47)	0.618
TnT negative patients
AC. mortality, 𝑛 (%)	14 (15.9)	28 (14.1)	15 (7.0)	4 (4.3)	0.38 (0.12–1.17)	0.092
C. mortality, 𝑛 (%)	9 (10.2)	15 (7.6)	7 (3.3)	2 (2.2)	0.28 (0.06–1.28)	0.100
SCD, 𝑛 (%)	7 (8.0)	8 (4.0)	5 (2.3)	1 (1.1)	0.18 (0.02–1.45)	0.106

HR (95% CI): hazard ratio (95% confidence interval).
HRs for low as compared to high socioeconomic group are depicted in the first section of the table. The lower section of the table shows the *HRs for patients without social security as compared to the high socioeconomic group, in which all patients had a social security program.
Variables included in the multivariate model are gender and age.
AC: all cause, C: cardiac, SCD: sudden cardiac death, 5 y: 5 years, FU: follow-up.

(b)  

Mode of death at 5 y FU		Low	Middle	High	HR (95% CI)	𝑃 value
All patients
AC. mortality, 𝑛 (%)		102 (22.8)	57 (15.0)	14 (9.0)	0.42 (0.22–0.80)	0.008
C. mortality, 𝑛 (%)		55 (12.3)	29 (7.7)	8 (5.2)	0.39 (0.15–0.99)	0.047
SCD, 𝑛 (%)		36 (8.0)	18 (4.7)	5 (3.2)	0.37 (0.13–1.06)	0.065
	Without social security				*HR (95% CI)
All patients
AC. mortality, 𝑛 (%)	38 (24.5)	64 (21.3)	57 (15.4)	14 (9.0)	0.46 (0.23–0.94)	0.032
C. mortality, 𝑛 (%)	24 (15.5)	31 (10.3)	29 (7.8)	8 (5.2)	0.37 (0.14–1.01)	0.054
SCD, 𝑛 (%)	15 (9.7)	21 (7.0)	18 (4.9)	5 (3.2)	0.47 (0.15–1.53)	0.211
TnT positive patients
AC. mortality, 𝑛 (%)	24 (35.8)	36 (35.0)	42 (27.1)	10 (15.9)	0.36 (0.15–0.83)	0.017
C. mortality, 𝑛 (%)	15 (22.4)	16 (15.5)	22 (14.2)	6 (9.5)	0.31 (0.10–0.98)	0.046
SCD, 𝑛 (%)	8 (11.9)	13 (12.6)	13 (8.4)	4 (6.3)	0.56 (0.13–2.36)	0.430
TnT negative patients
AC. mortality, 𝑛 (%)	14 (15.9)	28 (14.1)	15 (7.0)	4 (4.3)	0.45 (0.13–1.63)	0.224
C. mortality, 𝑛 (%)	9 (10.2)	15 (7.6)	7 (3.3)	2 (2.2)	0.28 (0.03–2.30)	0.233
SCD, 𝑛 (%)	7 (8.0)	8 (4.0)	5 (2.3)	1 (1.1)	0.27 (0.03–2.38)	0.240

HR (95% CI): hazard ratio (95% confidence interval).
HRs for low as compared to high socioeconomic group are depicted in the first section of the table. The lower section of the table shows the *HRs for patients without social security as compared to the high socioeconomic group, in which all patients had a social security program.
Variables potentially included in the stepwise multivariate model: gender, age, smoking, hypertension, index diagnosis, DM, CHF, history of previous CHD, hypercholesterolemia/use of statins, TnT > 0.01 ng/mL, eGFR, hsCRP, BNP, 25(OH)D, body mass index (kg/m²), months of sampling, and beta blockers prior to enrolment.
AC: all cause, C: cardiac, SCD: sudden cardiac death, 5 y: 5 years, FU: follow-up. DM: diabetes mellitus, CHF: congestive heart failure, CHD: coronary heart disease, eGFR: estimated glomerular filtration rate, hsCRP: high sensitivity C reactive protein, BNP: brain natriuretic peptide, 25(OH)D: vitamin D.